Clift, Ashley Kieran; Coupland, Carol AC; Keogh, Ruth H; Hemingway, Harry; Hippisley-Cox, Julia; (2021) COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults. Annals of Internal Medicine , 174 (4) pp. 572-576. 10.7326/M20-4986.

Preview

Text COVID-19 Mortality Risk in Down Syndrome Results From a Cohort Study of 8 Million Adults.pdf - Published Version Download (107kB) | Preview

Abstract

Background: At the start of the coronavirus disease 2019 (COVID-19) pandemic, many national health organizations emphasized nonpharmacologic interventions, such as quarantining or physical distancing. In the United Kingdom, strict self-isolation (“shielding”) was advised for those deemed to be clinically extremely vulnerable on the basis of the presence of selected medical conditions or at the discretion of their general practitioners. Down syndrome features on neither the U.K. shielding list nor the U.S. Centers for Disease Control and Prevention list of groups at “increased risk.” However, it is associated with immune dysfunction, congenital heart disease, and pulmonary pathology and, given its prevalence, may be a relevant albeit unconfirmed risk factor for severe COVID-19

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item